{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:22:02Z","timestamp":1760710922690,"version":"build-2065373602"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","criticalcare.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Care Clinics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ccc.2021.11.003","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T18:13:53Z","timestamp":1648750433000},"page":"243-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Undiagnosed and Rare Diseases in Critical Care"],"prefix":"10.1016","volume":"38","author":[{"given":"Bridget E.","family":"Shields","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolyn A.","family":"Wanat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne E.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ccc.2021.11.003_bib1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: dress)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"issue":"9","key":"10.1016\/j.ccc.2021.11.003_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1468-3083.2008.02585.x","article-title":"Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan","volume":"22","author":"Chiou","year":"2008","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.003_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17843286.1999.11754231","article-title":"Drug rash with eosinophilia and systemic symptoms (DRESS syndrome)","volume":"54","author":"Tas","year":"1999","journal-title":"Acta Clin Belg"},{"issue":"5","key":"10.1016\/j.ccc.2021.11.003_bib4","doi-asserted-by":"crossref","first-page":"693.e1","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: part I. Clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.ccc.2021.11.003_bib5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1365-2230.2010.03820.x","article-title":"Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions","volume":"35","author":"Hirahara","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2230.2008.02823.x","article-title":"Drug rash with eosinophilia and systemic symptoms and graft-versus-host disease developing sequentially in a patient","volume":"34","author":"Natkunarajah","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2133.2006.07238.x","article-title":"Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease","volume":"155","author":"Kano","year":"2006","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/DAD.0b013e3181a18d64","article-title":"Drug-induced hypersensitivity syndrome with superficial granulomatous dermatitis--a novel finding","volume":"31","author":"Fernando","year":"2009","journal-title":"Am J Dermatopathol"},{"issue":"5","key":"10.1016\/j.ccc.2021.11.003_bib9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaad.2009.08.050","article-title":"Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients","volume":"63","author":"Ang","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.003_bib11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.iac.2009.04.007","article-title":"The variable clinical picture of drug-induced hypersensitivity syndrome\/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug","volume":"29","author":"Kano","year":"2009","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.003_bib12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.mcna.2010.03.004","article-title":"Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome","volume":"94","author":"Kano","year":"2010","journal-title":"Med Clin North Am"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.003_bib13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaad.2010.12.013","article-title":"Fulminant myocarditis as a late sequela of DRESS: two cases","volume":"65","author":"Bourgeois","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.003_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"issue":"5","key":"10.1016\/j.ccc.2021.11.003_bib16","doi-asserted-by":"crossref","first-page":"709.e1","DOI":"10.1016\/j.jaad.2013.01.032","article-title":"DRESS syndrome: part II. Management and therapeutics","volume":"68","author":"Husain","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2332\/allergolint.55.1","article-title":"Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses","volume":"55","author":"Shiohara","year":"2006","journal-title":"Allergol Int"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib18","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jamadermatol.2020.0048","article-title":"Evaluation of cyclosporine for the treatment of DRESS syndrome","volume":"156","author":"Nguyen","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib19","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1542\/peds.107.1.e14","article-title":"Successful treatment of antiepileptic drug hypersensitivity syndrome with intravenous immune globulin","volume":"107","author":"Scheuerman","year":"2001","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.003_bib20","first-page":"510","article-title":"Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG)","volume":"4","author":"Fields","year":"2005","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.003_bib21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archderm.148.4.dlt120002-c","article-title":"Poor benefit\/risk balance of intravenous immunoglobulins in DRESS","volume":"148","author":"Joly","year":"2012","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an update","volume":"16","author":"Dodiuk-Gad","year":"2015","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.ccc.2021.11.003_bib24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib25","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jaad.2020.02.066","article-title":"Society of dermatology hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults","volume":"82","author":"Seminario-Vidal","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib26","doi-asserted-by":"crossref","first-page":"173.e1","DOI":"10.1016\/j.jaad.2013.05.003","article-title":"Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis","volume":"69","author":"Schwartz","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.ccc.2021.11.003_bib28","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.jaad.2018.10.058","article-title":"Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and patients' characteristics","volume":"80","author":"Chaby","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.ccc.2021.11.003_bib29","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch Dermatol"},{"issue":"24","key":"10.1016\/j.ccc.2021.11.003_bib30","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccc.2021.11.003_bib31","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ccc.2021.11.003_bib33","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib34","doi-asserted-by":"crossref","first-page":"187.e1","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.ccc.2021.11.003_bib35","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/jamadermatol.2019.0998","article-title":"The ABCD-10 risk prediction model for in-hospital mortality among patients with stevens-johnson syndrome\/toxic epidermal necrolysis-reply","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.003_bib36","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with stevens-johnson syndrome\/toxic epidermal necrolysis-ABCD-10","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib37","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib38","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.pain.2011.01.055","article-title":"Pregabalin in severe burn injury pain: a double-blind, randomised placebo-controlled trial","volume":"152","author":"Gray","year":"2011","journal-title":"Pain"},{"issue":"18","key":"10.1016\/j.ccc.2021.11.003_bib39","doi-asserted-by":"crossref","first-page":"e15343","DOI":"10.1097\/MD.0000000000015343","article-title":"Pregabalin in the reduction of pain and opioid consumption after burn injuries: a preliminary, randomized, double-blind, placebo-controlled study","volume":"98","author":"Jones","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib40","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.burns.2017.07.018","article-title":"Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: a retrospective chart review","volume":"44","author":"Kaul","year":"2018","journal-title":"Burns"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.burns.2016.07.026","article-title":"Steven johnson syndrome and toxic epidermal necrolysis in a burn unit: a 15-year experience","volume":"43","author":"McCullough","year":"2017","journal-title":"Burns"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.003_bib42","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.jaad.2017.05.057","article-title":"Prognosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"77","author":"Schneider","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib43","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4103\/0378-6323.191134","article-title":"Guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis: an Indian perspective","volume":"82","author":"Gupta","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A\u00a0multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J\u00a0Burn Care Rehabil"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib47","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1346-8138.2009.00770.x","article-title":"Toxic epidermal necrolysis with severe hyperbilirubinemia: complete re-epithelialization after bilirubin reduction therapies","volume":"37","author":"Kamada","year":"2010","journal-title":"J\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","article-title":"Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures","volume":"89","author":"de Prost","year":"2010","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3904\/kjim.2012.27.2.203","article-title":"Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients","volume":"27","author":"Kim","year":"2012","journal-title":"Korean J Intern Med"},{"issue":"8","key":"10.1016\/j.ccc.2021.11.003_bib50","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2230.2010.03826.x","article-title":"Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre","volume":"35","author":"Rajaratnam","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.003_bib51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A\u00a010-year experience with toxic epidermal necrolysis","volume":"21","author":"Schulz","year":"2000","journal-title":"J\u00a0Burn Care Rehabil"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00134-009-1659-1","article-title":"Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes","volume":"36","author":"Struck","year":"2010","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.003_bib53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jaad.2020.04.020","article-title":"Long-term sequelae from Stevens-Johnson syndrome\/toxic epidermal necrolysis in a large retrospective cohort","volume":"84","author":"Wang","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib54","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jamadermatol.2021.1136","article-title":"Long-term physical and psychological outcomes of stevens-johnson syndrome\/toxic epidermal necrolysis","volume":"157","author":"Hoffman","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib55","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/pde.14472","article-title":"Clinical features of recurrent Mycoplasma pneumoniae-induced rash and mucositis","volume":"38","author":"Liakos","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib56","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/pde.14419","article-title":"Adenoviral-induced rash and mucositis: expanding the spectrum of reactive infectious mucocutaneous eruption","volume":"38","author":"G\u00e1mez-Gonz\u00e1lez","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jaad.2014.06.026","article-title":"Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review","volume":"72","author":"Canavan","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.003_bib58","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CMR.00114-16","article-title":"Mycoplasma pneumoniae from the respiratory tract and beyond","volume":"30","author":"Waites","year":"2017","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib59","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1177\/1203475419874444","article-title":"Treatment of","volume":"23","author":"Li","year":"2019","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib60","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamadermatol.2020.5166","article-title":"Evaluation of etanercept for treatment of reactive infectious mucocutaneous eruption","volume":"157","author":"Miller","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib61","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.5546\/aap.2013.e24","article-title":"[Toxic epidermal necrolysis associated with acute infection by Mycoplasma pneumoniae]","volume":"111","author":"Calvano","year":"2013","journal-title":"Arch Argent Pediatr"},{"issue":"5","key":"10.1016\/j.ccc.2021.11.003_bib62","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/RHU.0000000000000830","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis-like lupus erythematosus","volume":"25","author":"Tankunakorn","year":"2019","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.ccc.2021.11.003_bib63","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/0961203313492242","article-title":"A\u00a0case of toxic epidermal necrolysis-like skin lesions with systemic lupus erythematosus and review of the literature","volume":"22","author":"Yildirim Cetin","year":"2013","journal-title":"Lupus"},{"issue":"29","key":"10.1016\/j.ccc.2021.11.003_bib64","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1097\/MD.0000000000000346","article-title":"Neutrophilic skin lesions in autoimmune connective tissue diseases: nine cases and a literature review","volume":"93","author":"Hau","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib65","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/0961203308089341","article-title":"Efficacy of plasmapheresis in the treatment of refractory toxic epidermal necrolysis-like acute cutaneous lupus erythematosus","volume":"17","author":"Simsek","year":"2008","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.003_bib66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/RHU.0000000000000088","article-title":"Systemic lupus erythematosus presenting as Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"20","author":"Baker","year":"2014","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"20","key":"10.1016\/j.ccc.2021.11.003_bib67","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.3390\/ijms20205023","article-title":"Methotrexate an old drug with new tricks","volume":"20","author":"Bedoui","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.003_bib68","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate--how does it really work?","volume":"6","author":"Chan","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.003_bib69","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jaad.2017.02.021","article-title":"Methotrexate-induced epidermal necrosis: a case series of 24 patients","volume":"77","author":"Chen","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.003_bib70","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/pde.14591","article-title":"High-dose methotrexate-induced epidermal necrosis in two pediatric patients","volume":"38","author":"Ravi","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"9","key":"10.1016\/j.ccc.2021.11.003_bib71","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/ddg.14176","article-title":"Methotrexate-induced epidermal necrosis in a child with osteosarcoma","volume":"18","author":"Tom\u00e1s-Vel\u00e1zquez","year":"2020","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.003_bib72","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.det.2019.05.014","article-title":"Review of graft-versus-host disease","volume":"37","author":"Ramachandran","year":"2019","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib73","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.003_bib74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40257-017-0306-9","article-title":"Cutaneous graft-versus-host disease: diagnosis and treatment","volume":"19","author":"Strong Rodrigues","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"10.1016\/j.ccc.2021.11.003_bib75","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/cup.12986","article-title":"A\u00a0pilot study comparing histological and immunophenotypic patterns in stage 4 skin graft vs host disease from toxic epidermal necrolysis","volume":"44","author":"Naik","year":"2017","journal-title":"J\u00a0Cutan Pathol"},{"issue":"9","key":"10.1016\/j.ccc.2021.11.003_bib76","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/10428194.2017.1422867","article-title":"Toxic epidermal necrolysis versus cutaneous graft-versus-host disease in a hematopoietic stem cell transplant recipient: the role of elafin","volume":"59","author":"Chen","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.ccc.2021.11.003_bib77","first-page":"2288","article-title":"Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation","volume":"92","author":"Van Lint","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.003_bib78","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2014.118471","article-title":"Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial","volume":"100","author":"Mielcarek","year":"2015","journal-title":"Haematologica"}],"container-title":["Critical Care Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070421000890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070421000890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:13:44Z","timestamp":1760062424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749070421000890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0749070421000890"],"URL":"https:\/\/doi.org\/10.1016\/j.ccc.2021.11.003","relation":{},"ISSN":["0749-0704"],"issn-type":[{"type":"print","value":"0749-0704"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Undiagnosed and Rare Diseases in Critical Care","name":"articletitle","label":"Article Title"},{"value":"Critical Care Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccc.2021.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}